These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26689236)

  • 1. One size does not fit all: Challenging some dogmas and taboos in drug discovery.
    Chai CL; Mátyus P
    Future Med Chem; 2016 Jan; 8(1):29-38. PubMed ID: 26689236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors.
    Leung CH; Chan DS; Kwan MH; Cheng Z; Wong CY; Zhu GY; Fong WF; Ma DL
    ChemMedChem; 2011 May; 6(5):765-8. PubMed ID: 21365767
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening.
    Wang Y; Law WK; Hu JS; Lin HQ; Ip TM; Wan DC
    J Chem Inf Model; 2014 Nov; 54(11):3046-50. PubMed ID: 25360897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polypharmacology of natural products.
    Ho TT; Tran QT; Chai CL
    Future Med Chem; 2018 Jun; 10(11):1361-1368. PubMed ID: 29673257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology.
    Gilberg E; Jasial S; Stumpfe D; Dimova D; Bajorath J
    J Med Chem; 2016 Nov; 59(22):10285-10290. PubMed ID: 27809519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.
    Coussens NP; Braisted JC; Peryea T; Sittampalam GS; Simeonov A; Hall MD
    Pharmacol Rev; 2017 Oct; 69(4):479-496. PubMed ID: 28931623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacological drug actions of recently FDA approved antibiotics.
    Wetzel C; Lonneman M; Wu C
    Eur J Med Chem; 2021 Jan; 209():112931. PubMed ID: 33127170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules.
    Dutta D; Das R; Mandal C; Mandal C
    J Chem Inf Model; 2018 Jan; 58(1):68-89. PubMed ID: 29243930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries.
    Franzini RM; Neri D; Scheuermann J
    Acc Chem Res; 2014 Apr; 47(4):1247-55. PubMed ID: 24673190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic assays for chemical biology and drug discovery.
    Gul S
    Clin Epigenetics; 2017; 9():41. PubMed ID: 28439316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery.
    Taylor RD; MacCoss M; Lawson AD
    J Med Chem; 2017 Mar; 60(5):1638-1647. PubMed ID: 27935308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Small-Molecule Reactivity Identifies Promiscuous Bioactive Compounds.
    Matlock MK; Hughes TB; Dahlin JL; Swamidass SJ
    J Chem Inf Model; 2018 Aug; 58(8):1483-1500. PubMed ID: 29990427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of off-target effects on angiotensin-converting enzyme 2.
    Kulemina LV; Ostrov DA
    J Biomol Screen; 2011 Sep; 16(8):878-85. PubMed ID: 21859683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing small-molecule-based chemical biology with next-generation sequencing technologies.
    Anandhakumar C; Kizaki S; Bando T; Pandian GN; Sugiyama H
    Chembiochem; 2015 Jan; 16(1):20-38. PubMed ID: 25421391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
    Tamatam R; Mohammed A
    Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A High-Throughput Screening Platform Identifies FDA-Approved Drugs That Inhibit SREBP Pathway Activation.
    T Ishida C; Kubota CS; Carlyle E; Tsukamoto T; Espenshade PJ
    ACS Chem Biol; 2024 Aug; 19(8):1695-1704. PubMed ID: 39106256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.
    Li YH; Wang PP; Li XX; Yu CY; Yang H; Zhou J; Xue WW; Tan J; Zhu F
    PLoS One; 2016; 11(11):e0165737. PubMed ID: 27828998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.